Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study
Authors:
- Louisa PollockLPLouisa Pollock
- Karl A HoldenKHKarl A Holden
- Alasdair Ps MunroAMAlasdair Ps Munro
- Aisleen BennettABAisleen Bennett
- Thomas C WilliamsTWThomas C Williams
- Lance TurtleLTLance Turtle
- Cameron J FairfieldCFCameron J Fairfield
- Thomas M DrakeTDThomas M Drake
- Saul N FaustSFSaul N Faust
- Ian P SinhaISIan P Sinha
- Damian RolandDRDamian Roland
Preprint
Abstract
Background: Children and young people (CYP) were less affected than adults in the first wave of SARS-CoV-2 in the UK. We test the hypothesis that clinical characteristics of hospitalized CYP with SARS-CoV-2 in the UK second wave would differ from the first due to the combined impact of the alpha variant, school reopening and relaxation of shielding. Methods: Patients th January 2020 and 31 st January 2021. Minimum follow up time was two weeks. Clinical characteristics were compared between the first (W1) and second wave (W2) of infections. Findings: 2044 CYP aged <19 years were reported from 187 hospitals. 427/2044 (20.6%) had asymptomatic/incidental SARS-CoV-2 infection and were excluded from main analysis. 16.0% (248/1548) of symptomatic CYP were admitted to critical care and 0.8% (12/1504) died. 5.6% (91/1617) of symptomatic CYP had Multisystem Inflammatory Syndrome in Children (MIS-C). Patients in W2 were significantly older (median age 6.5 years, IQR 0.3-14.9) than W1 (4.0 (0.4-13.6, p 0.015). Fever was more common in W1, otherwise presenting symptoms and comorbidities were similar across waves. After excluding CYP with MIS-C, patients in W2 had lower PEWS at presentation, lower antibiotic use and less respiratory and cardiovascular support compared to W1. There was no change in the proportion of CYP admitted to critical care between W1 and W2. 58.0% (938/1617) of symptomatic CYP had no reported comorbidity. Patients without co-morbidities were younger (42.4%, 398/938, <1 year old), had lower Paediatric Early Warning Scores (PEWS) at presentation, shorter length of hospital stay and received less respiratory support. MIS-C was responsible for a large proportion of critical care admissions, invasive and non-invasive ventilatory support, inotrope and intravenous corticosteroid use in CYP without comorbidities. Interpretation: Severe disease in CYP admitted with symptomatic SARS-CoV-2 in the UK remains rare. One in five CYP in this cohort had asymptomatic/incidental SARS-CoV-2 infection. We found no evidence of increased disease severity in W2 compared with W1. Funding: Short form: National Institute for Health Research, UK Medical Research Council, Wellcome Trust, Department for International Development and the Bill and Melinda Gates Foundation. Long form: This work is supported by grants from the National Institute for Health Research (award CO-CIN-01) and the Medical Research Council (grant MC_PC_19059) and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907), Wellcome Trust and Department for International Development (215091/Z/18/Z), and the Bill and Melinda Gates Foundation (OPP1209135). Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference: C18616/A25153). JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust, or PHE.Keywords
All Related Versions
- Published version: Pediatric Research, 93 (1), 207.
This publication has 18 references indexed in Scilit:
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in EnglandScience, 2021
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraCell, 2021
- Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young peopleThe Lancet Child & Adolescent Health, 2021
- COVID-19 in children: current evidence and key questionsCurrent Opinion in Infectious Diseases, 2020
- COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyThe Lancet Child & Adolescent Health, 2020
- Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort studyBMJ, 2020
- COVID-19 in children: analysis of the first pandemic peak in EnglandArchives of Disease in Childhood, 2020
- Multisystem Inflammatory Syndrome in U.S. Children and AdolescentsNew England Journal of Medicine, 2020
- Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research NetworksEuropean Journal of Pediatrics, 2020
- Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyBMJ, 2020